Forrest discusses the systemic nature of peripheral neuropathy, emphasizing the role of demyelination and metabolic factors in neurological health. He highlights the exciting development of a brain product aimed at addressing issues like depression and anxiety by targeting underlying metabolic gaps. The potential for objective data to demonstrate the efficacy of these treatments is a key focus for the upcoming years.
